Literature DB >> 16838322

Sweet's syndrome in chronic lymphocytic leukemia associated with neutropenic fever and granulocyte colony stimulation factor.

Michael A Thompson1, Senait W Dyson, Stefan Faderl.   

Abstract

Granulocyte colony stimulation factor (G-CSF) is commonly used in the treatment of chemotherapy-induced myelosuppression. We report the case of a 62-year-old man with chronic lymphocytic leukemia who presented with neutropenic fever and sepsis. After treatment with G-CSF he developed Sweet's syndrome. Sweet's syndrome is a rare disorder but has been associated with cancer recurrence as well as administration of G-CSF. We present clinical and pathologic images that highlight the salient features of this entity. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838322     DOI: 10.1002/ajh.20666

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Rituximab for refractory subcutaneous Sweet's syndrome in chronic lymphocytic leukemia: A case report.

Authors:  Seyed Mehdi Hashemi; Seyed Amirhossein Fazeli; Abdolbaset Vahedi; Reza Golabchifard
Journal:  Mol Clin Oncol       Date:  2015-12-18

Review 2.  EPONYM. Sweet syndrome.

Authors:  Mi Jin Kim; Yon Ho Choe
Journal:  Eur J Pediatr       Date:  2010-05-06       Impact factor: 3.860

3.  Sweet syndrome in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: curious lymphocyte/neutrophil fluctuations.

Authors:  Ciğdem Usul Afşar; Semra Paydaş; Meral Günaldı; Berna Bozkurt Duman; Vehbi Erçolak; Suzan Zorludemir; Arbil Açıkalın
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

Review 4.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

Review 5.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

6.  Amelioration of cyclophosphamide-induced myelosuppression during treatment to rats with breast cancer through low-intensity pulsed ultrasound.

Authors:  Wei Wang; Dong Luo; Junlin Chen; Jinyun Chen; Yi Xia; Wenzhi Chen; Yan Wang
Journal:  Biosci Rep       Date:  2020-09-30       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.